BioVie Inc (@biovie.bsky.social)

@biovie.bsky.social Sep 15, 2026, 11:48 AM

A conference is scheduled for 8:30 am this morning to discuss the results. #ClinicalUpdate

@biovie.bsky.social Sep 15, 2026, 11:48 AM

Today, we announced positive results from our Phase 2 signal finding ADDRESS-LC trial evalulating bezisterim for the treatment of neurological symptoms associated with #LongCOVID. Read: investors.bioviepharma.com/news/news-de...

@biovie.bsky.social Sep 14, 2026, 8:15 PM

BioVie will host a conference call and webcast tomorrow, Tuesday, September 15, at 8:30am ET to discuss topline results from the Phase 2 ADDRESS-LC trial evaluating its investigational drug candidate bezisterim in #LongCOVID.

Register: lifescievents.com/event/bkvp81/

#ClinicalUpdate

BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long COVID

Tuesday, September 15, 2026 at 8:30 a.m. ET

@biovie.bsky.social Sep 8, 2026, 4:29 PM

Today, BioVie announced the next stage of engagement with the U.S. Food and Drug Administration (FDA) to advance the Phase 3 development program evaluating bezisterim in Parkinson’s disease.

#ParkinsonsDisease

PARKINSON’S UPDATE

BioVie Announces Update to Parkinson’s Phase 3 Development Program

@biovie.bsky.social Aug 31, 2026, 6:06 PM

We are grateful to our advisors living with #LongCOVID, and advocacy partners @solveme.bsky.social & @patientled.bsky.social whose efforts to raise awareness and educate communities helped support enrollment & participation in the study. Topline data results anticipated before end of September 2026.

@biovie.bsky.social Aug 31, 2026, 6:06 PM

Today, BioVie announced that the last on-treatment patient visit in the ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of #LongCOVID has been completed.